Silvia Olivares Mendoza, APRN
Acute Care · Oklahoma City, OKNPI 1811661614
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 277 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 25.0% of the total. 2025 is the largest year on record at $3,114, more than ten times the $179 reported in 2021. Among acute care clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 277 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$580
- Jazz Pharmaceuticals Inc.$398
- Insmed, Inc.$291
- Sanofi$271
- Amgen$254
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,39097%
- Education$1643%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 55 | $1,389 |
| GSK | 39 | $580 |
| Jazz Pharmaceuticals Inc. | 10 | $398 |
| Insmed, Inc. | 16 | $291 |
| Sanofi | 11 | $271 |
| Amgen | 15 | $254 |
| Mylan Specialty L.p. | 19 | $244 |
| Regeneron Healthcare Solutions, Inc. | 13 | $231 |
| United Therapeutics Corporation | 10 | $228 |
| Viatris Specialty LLC | 13 | $166 |
| Verona Pharma, Inc. | 15 | $162 |
| Pulmonx Corporation | 3 | $160 |
| Axsome Therapeutics, Inc. | 7 | $126 |
| Alnylam Pharmaceuticals Inc. | 6 | $126 |
| Harmony Biosciences LLC | 6 | $124 |
| Baxter Healthcare | 5 | $116 |
| Boehringer Ingelheim | 5 | $112 |
| Novartis | 5 | $94 |
| Philips North America LLC | 5 | $77 |
| Merck | 4 | $76 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $75 |
| Kestra Medical Technology Services, Inc. | 2 | $57 |
| Actelion Pharmaceuticals US, Inc. | 2 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Lilly USA, LLC | 2 | $47 |
| Pfizer | 2 | $34 |
| Inogen, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,554 in reported general payments places this provider in the 90th percentile of 266 acute care providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 56 | $52,424 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $39,477 |
| JardianceEmpagliflozin | 26 | $22,278 |
| FarxigaDapagliflozin Propanediol | 34 | $22,192 |
| EliquisApixaban | 33 | $22,122 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $17,820 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $16,127 |
| Spiriva RespimatTiotropium Bromide | 12 | $13,567 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 96 | $4,184 |
| Ipratropium Bromide | 123 | $3,842 |
| Tacrolimus | 15 | $1,799 |
| Montelukast Sodium | 78 | $1,148 |
| Metoprolol Succinate | 40 | $1,075 |
| Torsemide | 45 | $789 |
| Potassium Chloride | 34 | $775 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $580 | $55,60373 claims |
| NovartisEntresto | $94 | $52,42456 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,389 | $40,01360 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $112 | $35,84538 claims |
| PfizerEliquis | $34 | $22,12233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 266 acute care providers in Oklahoma.
Other acute care in Oklahoma City
- Karen GregoryOklahoma City$68K
- Katrina PyleOklahoma City$13K
- Deborah PeterOklahoma City$12K
- Christopher GordonOklahoma City$12K
- Kelli LeekOklahoma City$10K
- Scottie SmithOklahoma City$8K
- Maria BacaOklahoma City$7K
- Janet FundaroOklahoma City$7K
- Bonnie RenfroOklahoma City$5K
- Vicki OliverOklahoma City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.